A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus
Latest Information Update: 15 May 2024
Price :
$35 *
At a glance
- Drugs NNC0361-0041 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms TOPPLE T1D
- 09 May 2024 Status changed from active, no longer recruiting to completed.
- 28 Jun 2023 Planned End Date changed from 15 Jun 2024 to 1 May 2024.
- 28 Jun 2023 Planned primary completion date changed from 31 Aug 2023 to 1 Sep 2023.